Menstrual Health in Medicine: Addressing the Gender Gap in Care

Key Takeaways

• PMS affects up to 75% of menstruating individuals
• PMDD prevalence 3‑8%, linked to severe impairment
• Only 4.9% of Japanese workers seek medical care
• Historical gender bias left menstrual health underfunded
• Spain passed first menstrual‑leave law in 2023

Summary

The article highlights a persistent gender gap in medical care for menstrual health, noting that up to 75% of menstruating individuals experience PMS and 3‑8% suffer from PMDD, yet these conditions remain underdiagnosed and underfunded. A survey of 3,000 Japanese workers shows only 4.9% seek help despite productivity losses. Historical exclusion of women from research has left menstrual physiology a "black box," limiting effective treatments beyond off‑label SSRIs and contraceptives. The author urges clinicians, educators, and policymakers to validate symptoms, integrate training, and enact supportive legislation like Spain's 2023 menstrual‑leave law.

Pulse Analysis

Menstrual health has long lingered on the periphery of clinical research, despite affecting the majority of half the global population. Recent epidemiological data reveal that three‑quarters of menstruating individuals report premenstrual symptoms, and a notable minority meet criteria for premenstrual dysphoric disorder, a condition associated with heightened suicide risk and functional impairment. The disparity stems from decades of gender bias that excluded women from trials and relegated hormonal cycles to a nuisance variable, resulting in scant mechanistic insight and limited therapeutic options beyond off‑label antidepressants and hormonal contraceptives.

Clinicians now face a clear mandate to shift from dismissal to systematic evaluation. Incorporating validated questionnaires, routine screening during primary‑care visits, and personalized treatment plans can bridge the diagnostic gap. Medical curricula must expand beyond cursory reproductive physiology, embedding menstrual health into psychiatry, internal medicine, and primary‑care modules. Such educational reforms empower future providers to recognize PMDD as a distinct mood disorder, differentiate it from major depression, and prescribe evidence‑based interventions, thereby improving patient outcomes and reducing unnecessary referrals.

Policy interventions amplify clinical efforts by legitimizing menstrual health as a workplace and insurance concern. Spain's 2023 legislation, which grants menstrual leave, sets a precedent for accommodating the productivity losses documented in surveys of Japanese workers and other cohorts. In the United States, the absence of federal protection underscores an opportunity for advocacy groups and physician leaders to lobby for comparable statutes, insurance coverage, and research funding. Aligning clinical practice, education, and policy promises to transform menstrual health from a neglected niche into a mainstream component of equitable, evidence‑driven care.